First-in-human dose: current status review for better future perspectives

Aim The aim of this article is to understand the pros and cons of various methods involved in first-in-human (FIH) dose calculation and act decisively in dose escalations when calculating the maximum tolerated dose. Subjects and methods We reviewed early phase clinical trials for methods of FIH dose...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	European journal of clinical pharmacology Ročník 76; číslo 9; s. 1237 - 1243
Hlavní autoři:	Mishra, Archana, Sarangi, Sudhir Chandra, Reeta, Kh
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	Berlin/Heidelberg Springer Berlin Heidelberg 01.09.2020 Springer Nature B.V
Témata:	Antibodies, Monoclonal, Humanized - administration & dosage Antibodies, Monoclonal, Humanized - adverse effects Biomedical and Life Sciences Biomedicine Clinical Trial Clinical trials Clinical Trials, Phase I as Topic - methods Clinical Trials, Phase I as Topic - standards Cyclic N-Oxides - administration & dosage Cyclic N-Oxides - adverse effects Developmental stages Dose-Response Relationship, Drug Drug development Drug dosages Humans Maximum Tolerated Dose Pharmaceutical Preparations - administration & dosage Pharmacodynamics Pharmacokinetics Pharmacology/Toxicology Pyridines - administration & dosage Pyridines - adverse effects Research Design Reviews PK/PD modelling Phase 1 Dose escalation First-in-human dose MABEL NOAEL
ISSN:	0031-6970, 1432-1041, 1432-1041
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!